Eugenodilol: a third-generation beta-adrenoceptor blocker, derived from eugenol, with alpha-adrenoceptor blocking and beta2-adrenoceptor agonist-associated vasorelaxant activities

Journal of Cardiovascular Pharmacology
Y C HuangI J Chen


Eugenodilol, derived from natural eugenol, was first investigated with in vivo and in vitro models. In our in vivo study, eugenodilol (0.5, 1.0, and 1.5 mg/kg, i.v.) produced dose-dependent hypotensive and bradycardic responses in pentobarbital-anesthetized Wistar rats. Eugenodilol also inhibited the tachycardia and arterial pressor effects induced by (-)isoproterenol and phenylephrine, respectively. In our in vitro study, eugenodilol competitively antagonized (-)isoproterenol-induced positive inotropic and chronotropic effects and tracheal-relaxation responses on isolated guinea pig tissues in a concentration-dependent manner. The apparent pA2 values were 7.88+/-0.12 for right atria, 7.52+/-0.05 for left atria, and 7.33+/-0.15 for trachea, indicating that eugenodilol was a nonselective beta-adrenoceptor blocker. In thoracic aorta experiments, the apparent pA2 values of alpha-adrenoceptor blockade were 7.05+/-0.25 and 6.87+/-0.08 for eugenodilol and labetalol, respectively. In addition, eugenodilol produced cumulative relaxation responses on isolated guinea pig tracheal strips. The effects were competitively antagonized by ICI 118,551 (10(-8)-10(-6) M), a relatively selective beta2-adrenoceptor antagonist. In the radioligand-bi...Continue Reading


Apr 1, 1977·The Journal of General Physiology·R Deth, R Casteels
May 14, 1992·European Journal of Pharmacology·W F ChiouC F Chen
May 1, 1992·The American Journal of Medicine·E J Eichhorn
Feb 1, 1991·American Heart Journal·W H Frishman
Jan 1, 1985·Hypertension·P C ChangP Vermeij
Sep 1, 1966·The American Journal of Cardiology·S A Stephen
Apr 4, 1974·Pflügers Archiv : European journal of physiology·R Deth, C van Breemen
Sep 23, 1974·Biochemical and Biophysical Research Communications·R J LefkowitzM G Caron
May 1, 1980·Naunyn-Schmiedeberg's Archives of Pharmacology·P J MiachP Meyer
May 1, 1995·Journal of the American College of Cardiology·S L OlsenM R Bristow
May 26, 1995·Biochemical Pharmacology·P KumaraveluN S Devaraj
Mar 1, 1994·Journal of the American College of Cardiology·R N DoughtyN Sharpe
Jul 1, 1996·Journal of Cardiovascular Pharmacology·Y T LinI J Chen
Mar 1, 1959·British Journal of Pharmacology and Chemotherapy·O ARUNLAKSHANA, H O SCHILD
May 1, 1965·Journal of Medicinal Chemistry·J AUGSTEINC R WORTHING


Sep 1, 2006·Indian Journal of Clinical Biochemistry : IJCB·Rashmi ChoudharyC Subramanyam
Dec 14, 2011·Psychopharmacology·Chin-Wei HuangSheng-Nan Wu
Mar 21, 2003·Vascular Pharmacology·Carlos Estevam Nolf DamianiDalton Valentim Vassallo
Jan 4, 2005·Pharmacology·K NandakumarS H Bhardwaj
Jul 27, 2004·Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Médicas E Biológicas·J H Leal-CardosoA A C Albuquerque
May 22, 2002·Journal of Cardiovascular Pharmacology·Jwu-Lai YehIng-Jun Chen
Nov 15, 2002·Canadian Journal of Physiology and Pharmacology·J H Leal-CardosoPedro J C Magalhães

Related Concepts

Adrenergic beta-Agonists
Adrenergic beta-Antagonists
Anesthesia Procedures
Descending Aorta
Dose-Response Relationship, Drug
Drug Interactions

Related Feeds


Bradyarrhythmias are slow heart rates. Symptoms may include syncope, dizziness, fatigure, shortness of breath, and chest pains. Find the latest research on bradyarrhythmias here.

Adrenergic Receptors: Trafficking

Adrenergic receptor trafficking is an active physiological process where adrenergic receptors are relocated from one region of the cell to another or from one type of cell to another. Discover the latest research on adrenergic receptor trafficking here.